title: Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.
abstract: Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Here we identify inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration. These results establish that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for the treatment of Parkinson's disease.
authors: Neuroregeneration Program, Institute for Cell Engineering, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
authors: Byoung Dae
authors: BD
authors: Lee
authors: Joo-Ho
authors: JH
authors: Shin
authors: Jackalina
authors: J
authors: VanKampen
authors: Leonard
authors: L
authors: Petrucelli
authors: Andrew B
authors: AB
authors: West
authors: Han Seok
authors: HS
authors: Ko
authors: Yun-Il
authors: YI
authors: Lee
authors: Kathleen A
authors: KA
authors: Maguire-Zeiss
authors: William J
authors: WJ
authors: Bowers
authors: Howard J
authors: HJ
authors: Federoff
authors: Valina L
authors: VL
authors: Dawson
authors: Ted M
authors: TM
authors: Dawson
mesh_terms: D006801:Humans; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D009154:Mutation; D009474:Neurons / Q000502:physiology; D010300:Parkinson Disease / Q000235:genetics / Q000517:prevention & control*; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000187:drug effects / Q000235:genetics / Q000633:toxicity
chemical_list: D047428:Protein Kinase Inhibitors; C495280:LRRK2 protein, human; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D017346:Protein Serine-Threonine Kinases